• Je něco špatně v tomto záznamu ?

The Prognostic Importance of Impaired Fasting Glycemia in Chronic Coronary Heart Disease Patients

D. Slezák, O. Mayer, J. Bruthans, J. Seidlerová, M. Rychecká, J. Gelžinský, M. Mateřánková, P. Karnosová, P. Wohlfahrt, R. Cífková, J. Filipovský

. 2021 ; 129 (1) : 29-35. [pub] 20180829

Jazyk angličtina Země Německo

Typ dokumentu časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc22004709

Grantová podpora
Health Development Agency of the Czech Ministry of Health project 17-29520 A
Specific Academic Research Project of Charles University project SVV 260 393
Charles University Research Fund PROGRES, project Q39

OBJECTIVES: Impaired glucose metabolism represents one the most important cardiovascular risk factors, with steeply raising prevalence in overall population. We aimed to compare mortality risk of impaired fasting glycaemia (IFG) and overt diabetes mellitus (DM) in patients with coronary heart disease (CHD). STUDY DESIGN: prospective cohort study METHODS: A total of 1685 patients, 6-24 months after myocardial infarction and/or coronary revascularization at baseline, were followed in a prospective cohort study. Overt DM was defined as fasting glucose ≥ 7 mmol/L and/or use of antidiabetic treatment, while IFG as fasting glucose 5.6-6.99 mmol/L, but no antidiabetic medication. The main outcomes were total and cardiovascular mortality during 5 years of follow-up. RESULTS: During follow-up of 1826 days, 172 patients (10.2%) deceased, and of them 122 (7.2%) from a cardiovascular cause. Both exposures, overt DM (n=623, 37.0% of the whole sample) and IFG (n=436, 25.9%) were associated with an independent increase of 5-year total mortality, compared to normoglycemic subjects [fully adjusted hazard risk ratio (HRR) 1.63 (95%CI: 1.01-2.61)]; p=0.043 and 2.25 (95%CI: 1.45-3.50); p<0.0001, respectively]. In contrast, comparing both glucose disorders one with each other, no significant differences were found for total mortality [HRR 0.82 (0.53-1.28); p=0.33]. Taking 5-years cardiovascular mortality as outcome, similar pattern was observed [HRR 1.96 (95%CI: 1.06-3.63) and 3.84 (95%CI: 2.19-6.73) for overt DM and IFG, respectively, with HRR 0.63 (95%CI: 0.37-1.07) for comparison of both disorders]. CONCLUSIONS: Impaired fasting glycaemia adversely increases mortality of CHD patients in the same extent as overt DM.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc22004709
003      
CZ-PrNML
005      
20250325142742.0
007      
ta
008      
220113s2021 gw f 000 0|eng||
009      
AR
024    7_
$a 10.1055/a-0684-9601 $2 doi
035    __
$a (PubMed)30157533
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a gw
100    1_
$a Slezák, David $u Fakultni Nemocnice Plzen, 2nd Dept. of Internal Medicine, Plzen, Czech Republic
245    14
$a The Prognostic Importance of Impaired Fasting Glycemia in Chronic Coronary Heart Disease Patients / $c D. Slezák, O. Mayer, J. Bruthans, J. Seidlerová, M. Rychecká, J. Gelžinský, M. Mateřánková, P. Karnosová, P. Wohlfahrt, R. Cífková, J. Filipovský
520    9_
$a OBJECTIVES: Impaired glucose metabolism represents one the most important cardiovascular risk factors, with steeply raising prevalence in overall population. We aimed to compare mortality risk of impaired fasting glycaemia (IFG) and overt diabetes mellitus (DM) in patients with coronary heart disease (CHD). STUDY DESIGN: prospective cohort study METHODS: A total of 1685 patients, 6-24 months after myocardial infarction and/or coronary revascularization at baseline, were followed in a prospective cohort study. Overt DM was defined as fasting glucose ≥ 7 mmol/L and/or use of antidiabetic treatment, while IFG as fasting glucose 5.6-6.99 mmol/L, but no antidiabetic medication. The main outcomes were total and cardiovascular mortality during 5 years of follow-up. RESULTS: During follow-up of 1826 days, 172 patients (10.2%) deceased, and of them 122 (7.2%) from a cardiovascular cause. Both exposures, overt DM (n=623, 37.0% of the whole sample) and IFG (n=436, 25.9%) were associated with an independent increase of 5-year total mortality, compared to normoglycemic subjects [fully adjusted hazard risk ratio (HRR) 1.63 (95%CI: 1.01-2.61)]; p=0.043 and 2.25 (95%CI: 1.45-3.50); p<0.0001, respectively]. In contrast, comparing both glucose disorders one with each other, no significant differences were found for total mortality [HRR 0.82 (0.53-1.28); p=0.33]. Taking 5-years cardiovascular mortality as outcome, similar pattern was observed [HRR 1.96 (95%CI: 1.06-3.63) and 3.84 (95%CI: 2.19-6.73) for overt DM and IFG, respectively, with HRR 0.63 (95%CI: 0.37-1.07) for comparison of both disorders]. CONCLUSIONS: Impaired fasting glycaemia adversely increases mortality of CHD patients in the same extent as overt DM.
650    _2
$a senioři $7 D000368
650    _2
$a krevní glukóza $x metabolismus $7 D001786
650    _2
$a komorbidita $7 D015897
650    _2
$a nemoci koronárních tepen $x krev $x mortalita $7 D003324
650    _2
$a diabetes mellitus $x krev $x diagnóza $x farmakoterapie $x mortalita $7 D003920
650    _2
$a omezení příjmu potravy $x krev $7 D005215
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a následné studie $7 D005500
650    _2
$a lidé $7 D006801
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a lidé středního věku $7 D008875
650    _2
$a prediabetes $x krev $x mortalita $7 D011236
650    _2
$a prognóza $7 D011379
655    _2
$a časopisecké články $7 D016428
700    1_
$a Mayer, Otto $u Fakultni Nemocnice Plzen, 2nd Dept. of Internal Medicine, Plzen, Czech Republic
700    1_
$a Bruthans, Jan $u Fakultni Thomayerova nemocnice s poliklinikou, Centre for Cardiovascular Prevention , Praha, Czech Republic
700    1_
$a Seidlerová, Jitka $u Fakultni Nemocnice Plzen, 2nd Dept. of Internal Medicine, Plzen, Czech Republic
700    1_
$a Rychecká, Martina $u Fakultni Nemocnice Plzen, Dept. of Cardiology, Plzen, Czech Republic
700    1_
$a Gelžinský, Julius $u Fakultni Nemocnice Plzen, 2nd Dept. of Internal Medicine, Plzen, Czech Republic
700    1_
$a Mateřánková, Markéta $u Fakultni Nemocnice Plzen, 2nd Dept. of Internal Medicine, Plzen, Czech Republic
700    1_
$a Karnosová, Petra, $u Fakultni Nemocnice Plzen, 2nd Dept. of Internal Medicine, Plzen, Czech Republic $d 1985- $7 xx0330667
700    1_
$a Wohlfahrt, Peter $u Fakultni Thomayerova nemocnice s poliklinikou, Centre for Cardiovascular Prevention , Praha, Czech Republic
700    1_
$a Cífková, Renata $u Fakultni Thomayerova nemocnice s poliklinikou, Centre for Cardiovascular Prevention , Praha, Czech Republic
700    1_
$a Filipovský, Jan $u Fakultni Nemocnice Plzen, 2nd Dept. of Internal Medicine, Plzen, Czech Republic
773    0_
$w MED00009707 $t Experimental and clinical endocrinology & diabetes $x 1439-3646 $g Roč. 129, č. 1 (2021), s. 29-35
856    41
$u https://pubmed.ncbi.nlm.nih.gov/30157533 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20220113 $b ABA008
991    __
$a 20250325142743 $b ABA008
999    __
$a ok $b bmc $g 1752013 $s 1155858
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2021 $b 129 $c 1 $d 29-35 $e 20180829 $i 1439-3646 $m Experimental and clinical endocrinology & diabetes $n Exp Clin Endocrinol Diabetes $x MED00009707
GRA    __
$a Health Development Agency of the Czech Ministry of Health $p project 17-29520 A
GRA    __
$a Specific Academic Research Project of Charles University $p project SVV 260 393
GRA    __
$a Charles University Research Fund $p PROGRES, project Q39
LZP    __
$a Pubmed-20220113

Najít záznam

Citační ukazatele

Nahrávání dat ...

Možnosti archivace

Nahrávání dat ...